Opinion

Video

Efficacy and Safety Data from SunRISe-1

Author(s):

Gordon A. Brown, DO,Siamak Daneshmand, MD

The panel reviews data from the SunRISe-1 trial investigating TAR-200 and offers its impressions on the efficacy and safety findings.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      4 experts in this video
      Case 3: A 49-Year-Old Man With Recurrent Non–Muscle-Invasive Bladder Cancer
      4 experts in this video
      Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
      Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
      Study findings highlight gender gaps in oncology authorship and citation
      4 experts in this video
      Case 1: A 79-Year-Old Man With Non–Muscle-Invasive Bladder Cancer
      4 experts in this video
      Non–Muscle Invasive-Bladder Cancer Overview
      Laura Davis, MD, on link between microplastics and bladder cancer
      Laura Davis, MD, on link between microplastics and bladder cancer
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
      Expert discusses the NMIBC trials landscape
      John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
      John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
      Related Content
      Survey: New NMIBC treatments face slow uptake
      June 2nd 2025

      Survey: New NMIBC treatments face slow uptake

      Benjamin P. Saylor
      Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      June 1st 2025

      NIAGARA: ctDNA analysis highlights durvalumab’s impact in MIBC

      Benjamin P. Saylor
      The findings also lend further credence to the muscle-invasive bladder cancer treatment regimen, investigators reported.
      Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
      May 26th 2022

      Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

      Urology Times staff
      “We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.
      Thomas B. Powles, MBBS, MRCP, MD
      May 31st 2025

      EFS benefit is seen with sasanlimab in CIS and T1 NMIBC

      Benjamin P. Saylor
      "There was activity across all the groups from an EFS perspective," said Thomas B. Powles, MBBS, MRCP, MD.
      Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
      May 31st 2025

      Interim ENLIGHTED data show promise for padeliporfin VTP therapy in UTUC

      Benjamin P. Saylor
      Vitaly Margulis, MD, reported an overall response rate of 86.5%, and a complete response rate of 73%.
      © 2025 MJH Life Sciences

      All rights reserved.